Janux Therapeutics Ownership | Who Owns Janux Therapeutics?
Janux Therapeutics Ownership Summary
Janux Therapeutics is owned by 83.49% institutional investors, 7.75% insiders, and 8.76% retail investors. Ra capital management is the largest institutional shareholder, holding 18.69% of JANX shares. Fidelity Growth Compy Commingled Pl S is the top mutual fund, with 3.18% of its assets in Janux Therapeutics shares.
JANX Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Janux Therapeutics | 83.49% | 7.75% | 8.76% |
| Sector | Healthcare Stocks | 47.06% | 8.01% | 44.93% |
| Industry | Biotech Stocks | 44.97% | 7.82% | 47.21% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Ra capital management | 9.17M | 18.69% | $383.95M |
| Fmr | 7.78M | 15.86% | $325.80M |
| Orbimed advisors | 2.98M | 6.08% | $124.82M |
| Blackrock | 2.34M | 4.78% | $98.19M |
| Adage capital partners gp | 2.33M | 4.75% | $97.52M |
| Janus henderson group | 1.80M | 3.67% | $75.39M |
| Paradigm biocapital advisors lp | 1.56M | 3.19% | $65.53M |
| Vanguard group | 1.56M | 3.18% | $65.42M |
| Ecor1 capital | 1.47M | 3.00% | $61.57M |
| State street | 1.40M | 2.86% | $58.70M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Ra capital management | 9.17M | 5.08% | $383.95M |
| Cormorant asset management, lp | 1.05M | 2.54% | $43.98M |
| Logos global management lp | 750.00K | 2.53% | $31.42M |
| Paradigm biocapital advisors lp | 1.56M | 2.51% | $65.53M |
| Orbimed advisors | 2.98M | 2.48% | $124.82M |
| Vestal point capital, lp | 725.00K | 2.26% | $30.37M |
| Ecor1 capital | 1.47M | 1.88% | $61.57M |
| Avidity partners management lp | 840.22K | 1.50% | $35.20M |
| Ratan capital management lp | 105.76K | 1.34% | $4.43M |
| Stempoint capital lp | 92.95K | 1.14% | $3.89M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Paradigm biocapital advisors lp | 1.56M | 2.51% | 1.56M |
| Ecor1 capital | 1.47M | 1.88% | 1.47M |
| State street | 1.40M | 0.00% | 1.00M |
| Vestal point capital, lp | 725.00K | 2.26% | 725.00K |
| Blackrock | 2.34M | 0.00% | 650.02K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Orbimed advisors | 2.98M | 2.48% | -1.30M |
| Rtw investments, lp | - | - | -1.00M |
| Adage capital partners gp | 2.33M | 0.18% | -447.78K |
| Bvf inc/il | - | - | -441.53K |
| Samlyn capital | - | - | -324.70K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Paradigm biocapital advisors lp | 1.56M | 2.51% | 1.56M | $65.53M |
| Ecor1 capital | 1.47M | 1.88% | 1.47M | $61.57M |
| Vestal point capital, lp | 725.00K | 2.26% | 725.00K | $30.37M |
| Point72 asset management | 136.43K | 0.01% | 136.43K | $5.72M |
| Ensign peak advisors | 133.00K | 0.01% | 133.00K | $5.57M |
Sold Out
| Holder | Change |
|---|---|
| Abich financial wealth management | -20.00 |
| Pacer advisors | -439.00 |
| Metropolitan life insurance co/ny | -1.00K |
| Entrypoint capital | -1.65K |
| Bayesian capital management, lp | -5.60K |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2024 | 164 | 2.50% | 45,609,396 | 2.07% | 83 | 1.24% | 88 | -20.00% | 48 | 45.45% |
| Jun 30, 2024 | 159 | 28.23% | 44,686,120 | 5.66% | 91 | 0.99% | 109 | 26.74% | 33 | 17.86% |
| Mar 31, 2024 | 124 | 87.88% | 42,293,771 | 26.24% | 96 | 1.79% | 86 | 109.76% | 28 | 154.55% |
| Dec 31, 2023 | 66 | 11.86% | 33,501,724 | -4.59% | 73 | 1.04% | 41 | 28.13% | 11 | -31.25% |
| Sep 30, 2023 | 59 | 3.51% | 35,112,153 | 14.57% | 83 | 1.56% | 32 | 6.67% | 16 | 14.29% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Fidelity Growth Compy Commingled Pl S | 1.66M | 3.18% | 9.56K |
| Fidelity Growth Compy Commingled Pl O | 1.65M | 3.16% | 20.65K |
| Fidelity Growth Company Fund | 1.23M | 2.36% | -2.62K |
| Vanguard Total Stock Mkt Idx Inv | 1.00M | 1.92% | 1.61K |
| SPDR® S&P Biotech ETF | 724.52K | 1.39% | 8.02K |
| iShares Russell 2000 ETF | 722.59K | 1.38% | -1.62K |
| Fidelity Select Health Care | 650.00K | 1.25% | - |
| Fidelity Small Cap Growth | 644.64K | 1.24% | -1.69K |
| Janus Henderson Global Life Sciences D | 434.28K | 0.83% | 5.30K |
| Fidelity Advisor Health Care I | 428.00K | 0.82% | - |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Oct 28, 2024 | Campbell David Alan | President and CEO | Sell | $739.65K |
| Oct 28, 2024 | Campbell David Alan | President and CEO | Sell | $598.91K |
| Sep 13, 2024 | Lichter Jay | - | Sell | $178.08K |
| Oct 18, 2024 | RA CAPITAL MANAGEMENT, L.P. | Buy | $53.70M | |
| Oct 16, 2024 | Avalon Ventures XI, L.P. | - | Sell | $1.49M |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2024 Q4 | 1 | 19 |
| 2024 Q3 | - | 33 |
| 2024 Q2 | - | 8 |
| 2024 Q1 | 1 | - |
| 2023 Q4 | 3 | - |
JANX Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools